contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


kerecis-included-on-the-list-of-covered-products-for-diabetic-foot-ulcers-in-the-final-lcd-policy

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Coloplast er aktiv inden for medicinsk teknologi. Virksomheden er udvikler af produkter og tjenester tilpasset mennesker med forskellige medicinske tilstande. Virksomhedens produktportefølje består af plejeudstyr og bruges hovedsageligt inden for stomi, inkontinens, urologi og hud- og sårpleje. I dag opererer virksomheden på et globalt marked gennem egne salgskanaler. Virksomheden blev grundlagt i 1954 og har sit hovedkontor med beliggenhed i Humlebæk.

Coloplast

On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based...

On 14 November 2024, the U.S. Centers for Medicare &amp; Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed. Coloplast’s financial guidance for FY 2024/25 with organic growth of 8-9% and an EBIT margin before special items of around 28% is unchanged. The financial assumptions for Kerecis with a 3-year CAGR of around 30% until 2025/26 and an EBIT margin of around 20% (ex. PPA amortization) in FY 2025/26 are also unchanged. Once the policy is implemented, we expect loss of sales related to VLUs in the out-patient segment. At the same time, given that a significant number of products are removed from the covered list for DFUs, we expect sales growth to accelerate in this segment, therefore offsetting the loss of sales related to VLUs. <ol><li><a href="https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39764&amp;ver=8">LCD - Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (L39764)</a></li><li><a href="https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39763&amp;ver=8&amp;keyword=DL39764&amp;keywordType=starts&amp;areaId=all&amp;docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&amp;contractOption=all&amp;sortBy=relevance&amp;bc=1">Proposed LCD - Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (DL39764) (cms.gov)</a></li></ol> &nbsp; Contacts: Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Aleksandra Dimovska Vice President, Investor Relations +45 4911 2458 <a href="https://www.globenewswire.com/Tracker?data=ZWAC8uqhjXlTKcg35sCMgkglQtL6Y-UNY49sUAlh0ufshmIqlN22saJX_zM0d4FtsiXy0F6FAKyaFPxFljP0o7RPRQpOzPbEk_leRQxqRQM=">dkadim@coloplast.com</a> Press and media: Peter Mønster Sr. Media Relations Manager +45 4911 2623 <a href="https://www.globenewswire.com/Tracker?data=A8DHacEDGmCicIw7sMAjflyCxo3u1nYkArcyfKdvCUkQxvAf_jHt3wyrfxDgL3Cpe1nX6EpyQGq9XXQC7joPBa-aORZIadIEqOu_uQRTr-Q=">dkpete@coloplast.com</a> Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/1e7ccec1-fb93-44e8-b4bf-31302c9573c4">Coloplast_Final_LCD_policy_14112024</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTAxMzI1MCM0MDE5ODY5ODMjMjAwMjA2OQ=="> <img src="https://ml-eu.globenewswire.com/media/ZGJkMjljZGQtZGYzYi00NzA3LThiYmItYTc0ODdjNDg2ODZhLTEwMTM2NDI=/tiny/Coloplast-A-S.png">

Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy